CoChat

A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer

Open access
Kaur, Sukhbir, Elkahloun, Abdel G., Singh, Satya P., Chen, Qing-Rong, Meerzaman, Daoud M., Song, Timothy, Manu, Nidhi, Wu, Weiwei, Mannan, Poonam, Garfield, Susan H., Roberts, David D. · 2016 · Oncotarget
Cited by 107

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

// Sukhbir Kaur 1 , Abdel G. Elkahloun 2 , Satya P. Singh 3 , Qing-Rong Chen 4 , Daoud M. Meerzaman 4 , Timothy Song 1 , Nidhi Manu 1 , Weiwei Wu 2 , Poonam Mannan 4 , Susan H. Garfield 5 and David D. Roberts 1 1 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 2 Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA 3 Inflammation Biology Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA 4 Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 5 Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Correspondence to: David D. Roberts, email: // Keywords : CD47, cancer stem cells, triple-negative breast cancer, epidermal growth factor receptor, therapeutic antibodies Received : January 15, 2016 Accepted : January 21, 2016 Published : January 31, 2016 Abstract CD47 is a signaling receptor for thrombospondin-1 and the counter-receptor for signal-regulatory protein-α (SIRPα). By inducing inhibitory SIRPα signaling, elevated CD47 expression by some cancers prevents macrophage phagocytosis. The anti-human CD47 antibody B6H12 inhibits tumor growth in several xenograft models, presumably by preventing SIRPα engagement. However, CD47 signaling in nontransformed and some malignant cells regulates self-renewal, suggesting that CD47 antibodies may therapeutically target cancer stem cells (CSCs). Treatment of MDA-MB-231 breast CSCs with B6H12 decreased proliferation and asymmetric cell division. Similar effects were observed in T47D CSCs but not in MCF7 breast carcinoma or MCF10A breast epithelial cells. Gene expression analysis in breast CSCs treated with B6H12 showed decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factor KLF4. EGFR and KLF4 mRNAs are known targets of microRNA-7, and B6H12 treatment correspondingly enhanced microRNA-7 expression in breast CSCs. B6H12 treatment also acutely inhibited EGF-induced EGFR tyrosine phosphorylation. Expression of B6H12-responsive genes correlated with CD47 mRNA expression in human breast cancers, suggesting that the CD47 signaling pathways identified in breast CSCs are functional in vivo . These data reveal a novel SIRPα-independent mechanism by which therapeutic CD47 antibodies could control tumor growth by autonomously forcing differentiation of CSC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7100

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 107

Metadata

Authors
Kaur, S., Elkahloun, A. G., Singh, S. P., Chen, Q.-R., Meerzaman, D. M., Song, T., Manu, N., Wu, W., Mannan, P., Garfield, S. H., & Roberts, D. D.
Venue
Oncotarget
Published
2016-01-31
Volume
7
Issue
9
Pages
10133-10152
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2289935555
Cited by
107
References
4
FWCI
5.38
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. https://app.cochat.ai/papers/10.18632/oncotarget.7100
The paper
Kaur, S., Elkahloun, A. G., Singh, S. P., Chen, Q.-R., Meerzaman, D. M., Song, T., Manu, N., Wu, W., Mannan, P., Garfield, S. H., & Roberts, D. D. (2016). A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget. https://doi.org/10.18632/oncotarget.7100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.